KYMR
NASDAQ
US
Kymera Therapeutics, Inc. - Common Stock
$85.40
▲ +$0.47
(+0.55%)
Vol 691K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$6.1B
ROE
-33.4%
Margin
-674.8%
D/E
0.39
Beta
2.24
52W
$19–$103
Wall Street Consensus
29 analysts · Apr 202611
Strong Buy
16
Buy
2
Hold
0
Sell
0
Strong Sell
93.1%
Buy Rating
Price Chart
Similar Stocks
NUVL
Nuvalent, Inc
$7.3B
KRYS
Krystal Biotech Inc
P/E 35.9
$7.1B
HALO
Halozyme Therapeutics Inc
P/E 13.3
$7.9B
IBRX
Immunitybio Inc
$2.0B
ACLX
Arcellx Inc
$3.8B
PTGX
Protagonist Therapeutics Inc
P/E 118.9
$5.5B
RYTM
Rhythm Pharmaceuticals Inc
$7.1B
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.81 | $-0.97 | $-0.16 |
| Sep 2025 | $-0.82 | $-0.94 | $-0.12 |
| Jun 2025 | $-0.83 | $-0.95 | $-0.12 |
| Mar 2025 | $-0.93 | $-0.82 | +$0.11 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -31.6% | -31.6% | -31.6% | -31.6% | -33.4% | -33.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -667.6% | -616.0% | -616.0% | -616.0% | -674.8% | -674.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.42 | 0.42 | 0.42 | 0.42 | 0.39 | 0.39 |
| Current Ratio | 8.32 | 8.32 | 8.32 | 8.32 | 7.38 | 7.38 |
Key Ratios
ROA (TTM)
-28.6%
P/S (TTM)
140.46
P/B
3.1
EPS (TTM)
$-3.59
CF/Share
$-2.82
Rev Growth 3Y
-13.5%
52W High
$103.00
52W Low
$19.45
$19.45
52-Week Range
$103.00
How does KYMR compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
KYMR valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
140.5
▲
993%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
3.1
▲
27%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
KYMR profitability vs Biotechnology peers
ROE
-33.4%
▲
50%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-674.8%
▼
135%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-28.6%
▲
39%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
KYMR financial health vs Biotechnology peers
D/E ratio
0.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
7.4
▲
66%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
2.2
▲
131%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
KYMR fundamentals radar
KYMR
Peer median
Industry
KYMR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
KYMR vs peers: key metrics
Latest News
No related news yet